the epipodophyllotoxin derivative vp 16 -- 213 ( nsc 141540 ) was studied by the cancer and leukemia group b in a broad phase ii trial at three dose levels : 60 mg/m2 , 90 mg/m2 , and 135 mg/m2 i.v . twice weekly .
C0006826
cancer
C0023418
group